Present and future therapeutic strategies for melioidosis and glanders

D. Mark Estes, Steven W. Dow, Herbert P. Schweizer, Alfredo Torres

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Burkholderia pseudomallei and Burkholderia mallei are the causative agents of melioidosis and glanders, respectively. Both Gram-negative pathogens are endemic in many parts of the world. Although natural acquisition of these pathogens is rare in the majority of countries, these bacteria have recently gained much interest because of their potential as bioterrorism agents. In modern times, their potential destructive impact on public health has escalated owing to the ability of these pathogens to cause opportunistic infections in diabetic and perhaps otherwise immunocompromised people, two growing populations worldwide. For both pathogens, severe infection in humans carries a high mortality rate, both species are recalcitrant to antibiotic therapy - B. pseudomallei more so than B. mallei - and no licensed vaccine exists for either prophylactic or therapeutic use. The potential malicious use of these organisms has accelerated the investigation of new ways to prevent and to treat the diseases. The availability of several B. pseudomallei and B. mallei genome sequences has greatly facilitated target identification and development of new therapeutics. This review provides a compilation of literature covering studies in antimelioidosis and antiglanders antimicrobial drug discovery, with a particular focus on potential novel therapeutic approaches to combat these diseases.

Original languageEnglish (US)
Pages (from-to)325-338
Number of pages14
JournalExpert Review of Anti-Infective Therapy
Volume8
Issue number3
DOIs
StatePublished - Mar 2010

Fingerprint

Burkholderia mallei
Glanders
Melioidosis
Burkholderia pseudomallei
Biological Warfare Agents
Opportunistic Infections
Therapeutic Uses
Drug Discovery
Therapeutics
Vaccines
Public Health
Genome
Anti-Bacterial Agents
Bacteria
Mortality
Infection
Population

Keywords

  • Antibiotics
  • Antimicrobial compounds
  • Burkholderia mallei
  • Burkholderia pseudomallei

ASJC Scopus subject areas

  • Infectious Diseases
  • Microbiology (medical)
  • Microbiology
  • Virology

Cite this

Present and future therapeutic strategies for melioidosis and glanders. / Estes, D. Mark; Dow, Steven W.; Schweizer, Herbert P.; Torres, Alfredo.

In: Expert Review of Anti-Infective Therapy, Vol. 8, No. 3, 03.2010, p. 325-338.

Research output: Contribution to journalArticle

Estes, D. Mark ; Dow, Steven W. ; Schweizer, Herbert P. ; Torres, Alfredo. / Present and future therapeutic strategies for melioidosis and glanders. In: Expert Review of Anti-Infective Therapy. 2010 ; Vol. 8, No. 3. pp. 325-338.
@article{33e2dc68d83d4d128978a5b66e77fd43,
title = "Present and future therapeutic strategies for melioidosis and glanders",
abstract = "Burkholderia pseudomallei and Burkholderia mallei are the causative agents of melioidosis and glanders, respectively. Both Gram-negative pathogens are endemic in many parts of the world. Although natural acquisition of these pathogens is rare in the majority of countries, these bacteria have recently gained much interest because of their potential as bioterrorism agents. In modern times, their potential destructive impact on public health has escalated owing to the ability of these pathogens to cause opportunistic infections in diabetic and perhaps otherwise immunocompromised people, two growing populations worldwide. For both pathogens, severe infection in humans carries a high mortality rate, both species are recalcitrant to antibiotic therapy - B. pseudomallei more so than B. mallei - and no licensed vaccine exists for either prophylactic or therapeutic use. The potential malicious use of these organisms has accelerated the investigation of new ways to prevent and to treat the diseases. The availability of several B. pseudomallei and B. mallei genome sequences has greatly facilitated target identification and development of new therapeutics. This review provides a compilation of literature covering studies in antimelioidosis and antiglanders antimicrobial drug discovery, with a particular focus on potential novel therapeutic approaches to combat these diseases.",
keywords = "Antibiotics, Antimicrobial compounds, Burkholderia mallei, Burkholderia pseudomallei",
author = "Estes, {D. Mark} and Dow, {Steven W.} and Schweizer, {Herbert P.} and Alfredo Torres",
year = "2010",
month = "3",
doi = "10.1586/eri.10.4",
language = "English (US)",
volume = "8",
pages = "325--338",
journal = "Expert Review of Anti-Infective Therapy",
issn = "1478-7210",
publisher = "Expert Reviews Ltd.",
number = "3",

}

TY - JOUR

T1 - Present and future therapeutic strategies for melioidosis and glanders

AU - Estes, D. Mark

AU - Dow, Steven W.

AU - Schweizer, Herbert P.

AU - Torres, Alfredo

PY - 2010/3

Y1 - 2010/3

N2 - Burkholderia pseudomallei and Burkholderia mallei are the causative agents of melioidosis and glanders, respectively. Both Gram-negative pathogens are endemic in many parts of the world. Although natural acquisition of these pathogens is rare in the majority of countries, these bacteria have recently gained much interest because of their potential as bioterrorism agents. In modern times, their potential destructive impact on public health has escalated owing to the ability of these pathogens to cause opportunistic infections in diabetic and perhaps otherwise immunocompromised people, two growing populations worldwide. For both pathogens, severe infection in humans carries a high mortality rate, both species are recalcitrant to antibiotic therapy - B. pseudomallei more so than B. mallei - and no licensed vaccine exists for either prophylactic or therapeutic use. The potential malicious use of these organisms has accelerated the investigation of new ways to prevent and to treat the diseases. The availability of several B. pseudomallei and B. mallei genome sequences has greatly facilitated target identification and development of new therapeutics. This review provides a compilation of literature covering studies in antimelioidosis and antiglanders antimicrobial drug discovery, with a particular focus on potential novel therapeutic approaches to combat these diseases.

AB - Burkholderia pseudomallei and Burkholderia mallei are the causative agents of melioidosis and glanders, respectively. Both Gram-negative pathogens are endemic in many parts of the world. Although natural acquisition of these pathogens is rare in the majority of countries, these bacteria have recently gained much interest because of their potential as bioterrorism agents. In modern times, their potential destructive impact on public health has escalated owing to the ability of these pathogens to cause opportunistic infections in diabetic and perhaps otherwise immunocompromised people, two growing populations worldwide. For both pathogens, severe infection in humans carries a high mortality rate, both species are recalcitrant to antibiotic therapy - B. pseudomallei more so than B. mallei - and no licensed vaccine exists for either prophylactic or therapeutic use. The potential malicious use of these organisms has accelerated the investigation of new ways to prevent and to treat the diseases. The availability of several B. pseudomallei and B. mallei genome sequences has greatly facilitated target identification and development of new therapeutics. This review provides a compilation of literature covering studies in antimelioidosis and antiglanders antimicrobial drug discovery, with a particular focus on potential novel therapeutic approaches to combat these diseases.

KW - Antibiotics

KW - Antimicrobial compounds

KW - Burkholderia mallei

KW - Burkholderia pseudomallei

UR - http://www.scopus.com/inward/record.url?scp=77649282315&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77649282315&partnerID=8YFLogxK

U2 - 10.1586/eri.10.4

DO - 10.1586/eri.10.4

M3 - Article

VL - 8

SP - 325

EP - 338

JO - Expert Review of Anti-Infective Therapy

JF - Expert Review of Anti-Infective Therapy

SN - 1478-7210

IS - 3

ER -